P
ersons with HIV infection are at increased risk for hepatitis B virus (HBV) infection due to common modes of acquisition. The incidence of acute HBV infection in U.S. HIV cohort studies is 1.1 to 1.6 cases per 100 person-years (1-3), substantially higher than the incidence in the U.S. population in 2014 (0.9 case per 100 000 persons) (4). The prevalence of chronic hepatitis B was 8% to 9% in HIV cohorts between 1996 and 2007 (2, 3) compared with 0.3% in all U.S. households during this period (5). Infection with HIV negatively affects all phases of the natural history of HBV infection. Compared with HBV monoinfected persons, those coinfected with HIV and HBV are at higher risk for chronic infection, presence of hepatitis B e antigen, higher HBV DNA levels, cirrhosis, primary hepatocellular carcinoma, and liver-related death (5-12).
About 35 years have passed since the introduction of hepatitis B vaccination in the United States (13), and more than 20 years have elapsed since the Advisory Committee on Immunization Practices first recommended hepatitis B vaccination for all persons with HIV (14) . After this recommendation, hepatitis B incidence following an HIV diagnosis decreased by 70% between the pre-highly active antiretroviral therapy (HAART) era and the HAART era. However, there was no further decrease in the incidence of hepatitis B in persons with HIV from 2000 to 2008 (1) and no reduction in the prevalence of chronic hepatitis B (3) or the incidence of end-stage liver disease among patients receiving medical care for HIV infection ("HIV patients") (15) . Liverrelated deaths among HIV patients, in which hepatitis B plays a central role, account for the largest proportion of deaths not related to AIDS (16, 17) .
In 2016, the World Health Organization resolved to eliminate HBV infection as a public health threat by 2030 (18). In 2017, the National Academies of Sciences, Engineering, and Medicine laid out a path to achieving this goal in the United States (19), and the U.S. Department of Health and Human Services National Viral Hepatitis Action Plan outlined strategies for achieving a 60% reduction in new hepatitis B cases by 2020 (20) . The plan establishes indicators for measuring progress toward universal vaccination of vulnerable adults, including persons with HIV. However, there are currently no nationally representative estimates of the percentage of HIV patients who are not vaccinated for hepatitis B against which progress can be measured. To address this knowledge gap and to assess hepatitis B vaccination among HIV patients as a quality-of-care indicator, we examined the prevalence of HIV patients without hepatitis B vaccination, immunity, or infection (candidates to initiate vaccination) and describe factors associated with subsequent vaccination of candidates.
tative, annual, cross-sectional estimates of behavioral and clinical characteristics of HIV-infected adults in the United States. Methods for MMP have been described in detail (21, 22) . During the 2009 to 2012 cycle years, MMP used a 3-stage, probability-proportional-to-size sampling design, in which U.S. states and territories were sampled, followed by facilities providing outpatient HIV clinical care in those jurisdictions, and then HIV-infected adults (aged ≥18 years) receiving care at those facilities. Data were collected from adults with at least 1 HIV clinical care visit to a participating facility between January and April of the cycle year in which they were sampled. Thus, findings describe adults receiving HIV clinical care during these periods. Data were collected retrospectively using face-to-face or telephone interviews and medical record abstractions during 4 annual data collection cycles between June 2009 and May 2013. Data collected during these cycles were combined for this analysis. All sampled states and territories participated in MMP. Facility response rates ranged from 76% to 85%, and patient response rates ranged from 49% to 53%. Data were weighted to account for known probabilities of selection in each state or territory, by facility, and for patients in selected facilities. Predictors of nonresponse were determined from analysis of data from sampled facilities and patients, and data were then weighted to adjust for nonresponse using established methods (23, 24) .
In accordance with guidelines for defining public health research (25, 26), the Centers for Disease Control and Prevention (CDC) determined that MMP was public health surveillance used for disease control, program, or policy purposes. Local institutional review board approval was obtained in participating states, territories, and facilities when required. Informed consent was obtained from all interviewed participants.
Measures

Primary Outcomes
Primary outcomes were no documentation of hepatitis B vaccination, immunity, or infection in the medical record (candidates to initiate vaccination) and subsequent initiation of hepatitis B vaccination among candidates. For each participant, we collected medical record data that had been recorded during the year before the patient interview (surveillance period) and during the interval between the date of first medical care after HIV diagnosis and the beginning of the surveillance period (medical history period) (Figure 1 ). Information was collected from the medical record at the sampled facility, including all attached records from other facilities. We recorded results from all hepatitis B surface antigen (HBsAg) tests; hepatitis B surface antibody (HBsAb) total and IgG tests; and hepatitis B core antibody (HBcAb) total, IgG, and IgM tests during both periods. We also collected qualitative and quantitative HBV DNA test results for the surveillance period. For both periods, we recorded all doses of hepatitis B and hepatitis A/B vaccine. For patients who were not vaccinated, we recorded the reason for deferral (previously vaccinated or previously infected) if it was documented. We categorized patients at the beginning and end of the surveillance period as being candidates versus noncandidates to initiate vaccination. Noncandidates included patients with either 1) documentation of at least 1 dose of hepatitis B vaccine or combination hepatitis A/B vaccine, or documentation that the reason for deferral was previous vaccination, or 2) documentation of immunity (defined as a positive HBsAb test result) or infection (positive HBsAg test result, HBcAb IgM, or detectable HBV DNA). Those with isolated HBcAb (total or IgG and no other markers of hepatitis B) and no documentation of vaccination were classified as candidates to initiate vaccination.
During the surveillance period, candidates were categorized as having received or not received at least 1 vaccine dose. Those who were not vaccinated were further categorized as having new documentation of either immunity or infection. Candidates who were not vaccinated and had no new documentation of infection or immunity were classified as continuing candidates to initiate vaccination. In addition, we determined whether candidates were prescribed antiretroviral agents that were dually active against HBV, including tenofovir disoproxil fumarate (tenofovir) alone, lamivudine or emtricitabine alone, or both tenofovir and either lamivudine or emtricitabine.
Clinical and Sociodemographic Variables
Clinical characteristics included lowest HIV disease stage attained (27) (CDC-defined AIDS, no CDCdefined AIDS and nadir CD4 count of 0.200 to 0.499 × 10 9 cells/L, or no CDC-defined AIDS and nadir 
Statistical Analysis
The analytic data set included records of 18 089 adult MMP participants with paired interviews and medical record abstractions. We computed frequencies and weighted percentages describing characteristics of persons receiving HIV medical care and 95% CIs for these descriptive parameters. Associations between vaccination during the 1-year surveillance period and facility characteristics, met and unmet service needs, and clinical and sociodemographic characteristics were evaluated with Rao-Scott chi-square tests. To assess possible confounding of associations between vaccination and sociodemographic characteristics by facility type, we stratified all associations by the RWHAP funding status of the facilities where patients received HIV care. We performed a sensitivity analysis to assess the effect of excluding patients at facilities with unknown RWHAP funding status on the estimate of vaccination prevalence during the surveillance period. All analyses were performed using procedures for survey data analysis in SAS/STAT, version 9.3 (SAS Institute).
Role of the Funding Source
This study was funded by the CDC, which was responsible for the design, conduct, and analysis of the study.
RESULTS
Among persons receiving medical care for HIV infection from 2009 to 2012, more than two thirds were aged at least 40 years, were male, and had CDCdefined AIDS, and approximately half had a mean CD4 count of at least 0.500 × 10 9 cells/L in the previous year (Table 1) . Overall, 41.3% were black, 34.4% were white, 19.4% were Hispanic or Latino, and 4.9% were of another race/ethnicity. Nearly half were MSM (48.2%), 23.4% were men who had sex with women only, and 25.6% were women who had sex with men.
Among U.S. HIV patients, 44.2% had no documentation of vaccination, immunity, or infection in the medical record at the beginning of the surveillance period and were classified as candidates to initiate vaccination ( Table 1 and Figure 2 ).
Status of Candidates to Initiate Vaccination at the End of the Surveillance Period
Among candidates to initiate vaccination, 9.6% were vaccinated during the surveillance period, 7.5% were not vaccinated but had new documentation of hepatitis B immunity or infection, and 82.9% were not vaccinated and had no new documentation of immunity or infection (continuing candidates to initiate vaccination) ( Table 2 ). Three quarters of candidates were prescribed ART regimens that were dually active against HBV (2.8% were prescribed tenofovir alone, 17.1% were prescribed lamivudine or emtricitabine alone, and 64.8% were prescribed tenofovir and either lamivudine or emtricitabine). At the end of the surveillance period, 36.7% of U.S. HIV patients remained candidates to initiate vaccination ( Table 1) .
Association of Vaccination During the Surveillance Period With Patient and Facility Characteristics
Vaccination of candidates during the surveillance period was associated with the type of facility where patients received HIV care. A significantly larger percentage of patients who received care at RWHAPfunded facilities versus non-RWHAP-funded facilities were vaccinated (12.5% vs. 3.7%; P < 0.001) ( Table 3) . Fewer patients who received care at private practices (vs. nonprivate practices) were vaccinated (5.6% vs. 11.8%; P < 0.001). Patient characteristics associated with a significantly higher prevalence of vaccination included income below the FPL, lower educational attainment, black race, younger age, recent homelessness, and a mean CD4 count less than 0.500 × 10 9 cells/L (P < 0.001 for each) ( Table 4) . Vaccination was not associated with having been prescribed ART or attaining viral suppression.
After stratification by facility RWHAP funding status, prevalence of vaccination during the surveillance period was not significantly associated with income below the FPL or educational attainment among patients receiving care at either facility type (Appendix Table, available at Annals.org). Status of RWHAP funding was ascertained for 91% of patients. The estimate of vaccination during the surveillance period was 1% higher when participants at facilities with unknown RWHAP funding status were included. Although previous studies have assessed hepatitis B vaccination among HIV patients, this is, to our knowl- (30) . In a French hospitalbased HIV cohort, among those with sufficient serologic testing, 68% were immunized against hepatitis B after natural infection or vaccination (31) . Although our estimates are generally within the range of estimates from these studies, methodological differences prevent direct comparison. Although vaccination prevalence was low across all facility types, it was substantially higher among patients at RWHAP-funded facilities, which is consistent with other indicators that patients who receive care at such facilities have better clinical outcomes than those at facilities without RWHAP funding (32) . Vaccination prevalence was marginally higher among patients with social determinants of poor health, at least partially because vulnerable patients disproportionately receive HIV care at RWHAP-funded facilities (32) .
Several factors might contribute to failure of clinicians to vaccinate HIV patients for hepatitis B, including deferral of vaccination because of reports of reduced immunogenicity among such patients (10, 33) , inconsistency of recommendations for timing and dosage of vaccination within and across guidelines (34 -37), deficiency of robust systems within health care facilities to support vaccination, and lack of access to affordable vaccines for some HIV patients.
Many clinicians are aware of reports of reduced immunogenicity of hepatitis B vaccine among HIV patients (17.5% to 88.6% after 3 doses) compared with the U.S. population (>90%) (10, 37) . These studies have reported an association between vaccine effectiveness and higher CD4 cell counts, but each has demonstrated that vaccination can be successful at all CD4 cell counts. Although we did not find substantially lower vaccination prevalence among patients with a CD4 count less than 0.200 × 10 9 cells/L, a previous study reported such an association (31) . Federal guidelines recommend vaccinating all patients with HIV during their first visit, immediately after drawing blood for serologic testing, and not deferring vaccination of patients presenting with a low CD4 cell count (34 -37 (44, 45) . Implementation of a nurse program for vaccination at 1 of the clinics in the Swiss HIV Cohort Study significantly increased the proportion of patients with hepatitis B immunity from 32% to 76% over a 3-year period (46) . Use of a hepatitis B vaccination form placed in patients' charts led to an increase in vaccination from 67% to 79% in a British outpatient HIV clinic (47) , suggesting that wider use of electronic clinical reminders may also be helpful. In addition, the U.S. Department of Health and Human Services recommends However, the cost of hepatitis B vaccination may be a barrier to implementing these recommendations. The National Academy of Medicine reports substantial variation in vaccine coverage and payment policies among public and private insurers. In addition, adults are not included in state systems for universal vaccine purchase and distribution (48). The National Academies of Sciences, Engineering, and Medicine recommend increasing funding for free hepatitis B vaccination for adults in order to achieve coverage goals (19, 48). The RWHAP allows use of funds to purchase and administer vaccines (49). However, the extent to which funds are used for this purpose is not known, and at least one quarter of HIV patients receive care at facilities that are not funded by RWHAP (32) . Lack of coverage for vaccination by some RWHAP-funded facilities could help explain why vaccination prevalence is low even at these facilities.
Although many HIV patients are susceptible to HBV infection, approximately 5 out of 6 vaccine candidates had been prescribed at least 1 antiretroviral agent that is dually active against HBV, and two thirds were prescribed 2 dually active drugs. An analysis of the Swiss HIV Cohort suggests that these medications likely confer protection against HBV acquisition (50) . Investigators reported an overall 70% reduction in the hazard of HBV infection among patients prescribed tenofovir alone, emtricitabine or lamivudine alone, or a combination of tenofovir and either emtricitabine or lamivudine compared with no reduction among patients prescribed other ART regimens. Patients in the Swiss HIV Cohort who were prescribed 2 dually active drugs had a 90% reduction in the hazard of incident HBV infection. However, although dually active ART may be effective for preventing HBV acquisition while it is being used, it should not be considered an alternative to vaccination, which may confer long-term immunity. Our study had limitations. First, given the moderate response rate of our survey, nonresponse bias is possible. However, we used standard methods to mitigate this possibility. We collected information on all sampled patients and facilities and compared characteristics of respondents and nonrespondents; on the basis of the results of these nonresponse analyses, the data were weighted to minimize nonresponse bias. In addition, our probabilistic sampling frame was rigorously constructed and geographically diverse and included urban and rural clinics, public and private facilities, providers who saw many and few patients with HIV, and jurisdictions with varying prevalence of HIV infection. Empirical research suggests that low response rates do not necessarily indicate nonresponse bias, particularly when probabilistic samples are drawn from rigorously constructed frames (51) . Second, the inclusion criterion requiring patients to have had a care visit during a 4-month window could have resulted in selection bias, with underrepresentation of persons receiving less frequent care. However, a sensitivity analysis using HIV Outpatient Study cohort data revealed no differences in clinical outcomes between patients with visits during January to April versus January to December (52) . Third, incomplete availability of medical records from outside facilities could have resulted in measurement error, with misclassification of participants as candidates to initiate vaccination. Although all vaccination and laboratory data documented in outside medical records attached to the record at the sampled facility were recorded, if outside records had been universally available, our estimates of documented vaccination, immunity, and infection would likely have been at least marginally higher (53) . Also, because medical record data were collected starting at the date of HIV diagnosis, patients with documentation of immunity, infection, or vaccination only before the date of diagnosis could have been misclassified as vaccination candidates. Fourth, the study was not designed to assess completion of the vaccine series or the actual prevalence of immunity among persons with HIV. A single vaccine dose typically is not immunogenic. However, the absence of at least 1 dose is a clear indicator of a missed opportunity to initiate vaccination. Finally, testing and subsequent vaccination for hepatitis B may have increased recently in connection with 2012 recommendations for routine hepatitis C screening of all persons born between 1945 and 1965 (54).
In conclusion, more than one third of U.S. HIV patients have not been vaccinated for hepatitis B. Only 1 in 10 of these vaccination candidates was vaccinated in the course of 1 year of ongoing HIV care. Meeting goals for hepatitis B elimination will require a multifaceted approach to increasing vaccination of HIV patients. Particular attention should be focused on increasing vaccination of patients who receive care in private practices or at facilities that are not funded by RWHAP.
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